Related Experiment Videos
CD25+ regulatory T cells and tumor immunity
Emma Jones1, Michaela Dahm-Vicker, Denise Golgher
1Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.
Immunology Letters
|January 16, 2003
Summary
Tumor cells present antigens, but immune responses are weak, failing to reject tumors. Regulatory T cells (CD25+) are identified as a key factor contributing to this poor tumor immunogenicity.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor cells express self and non-self antigens, eliciting immune responses in cancer patients and animal models.
- These anti-tumor immune responses are typically weak and insufficient for tumor rejection.
- Regulatory T cells, specifically CD25+ cells, are increasingly recognized as suppressors of anti-tumor immunity.
Purpose of the Study:
- To investigate the role of CD25+ regulatory T cells in suppressing anti-tumor immune responses.
- To understand the mechanisms behind the poor immunogenicity of tumor cells.
- To discuss the evidence in the context of a murine melanoma model.
Main Methods:
- Analysis of immune responses to tumor antigens in cancer patients and murine models.
- Identification and characterization of regulatory T cell populations (CD25+).
- Utilizing a murine model of melanoma to study immune evasion.
Main Results:
- Immune responses against tumor antigens are generally weak and ineffective in achieving tumor rejection.
- CD25+ regulatory T cells are implicated as a significant factor contributing to the suppressed anti-tumor immunity.
- Evidence supports the role of regulatory T cells in hindering effective anti-tumor immune responses.
Conclusions:
- CD25+ regulatory T cells play a crucial role in the immune evasion of tumors.
- Targeting regulatory T cells may represent a therapeutic strategy to enhance anti-tumor immunity.
- Further research in models like murine melanoma is vital for understanding and overcoming tumor-induced immunosuppression.